ASMB Assembly Biosciences
- 15.150
- +0.290+1.95%
- 15.290
- +0.140+0.92%
Assembly Biosciences News
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress 2024
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will present data from its herpes simplex virus (HSV) and hepatitis D virus (HDV) pipeline programs at upcoming medical congresses.
H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)
Assembly Biosciences Q1 EPS $(1.66) Beats $(3.24) Estimate
Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.66) per share which beat the analyst consensus estimate of $(3.24) by 48.77 percent. This is a 62.61 percent increase over losses of
Assembly Biosciences | 10-Q: Quarterly report
Assembly Biosciences 1Q Loss/Shr $1.66 >ASMB
Assembly Biosciences 1Q Loss/Shr $1.66 >ASMB
Assembly Biosciences 1Q Loss $9.08M >ASMB
Assembly Biosciences 1Q Loss $9.08M >ASMB
Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)
HC Wainwright & Co. Reiterates Neutral on Assembly Biosciences
HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.
Assembly Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 — HC Wainwright & Co. Reiterates → Neutral 03/24/2023 -88.46% HC Wainwright & Co. $2.5 → $1.5
Assembly Biosciences Q4 EPS $(1.74) Beats $(2.88) Estimate, Sales $7.16M
Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.74) per share which beat the analyst consensus estimate of $(2.88) by 39.58 percent. This is a 68.48 percent increase over losses of
Assembly Biosciences GAAP EPS of -$13.38 Beats by $0.90
Press Release: Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights -- Four candidates planned to be in clinical development in 2024 with interim data from
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating inter
Assembly Biosciences Welcomes New Board Member, Launches Bonus Plan
ASSEMBLY, A STAGWELL (STGW) AGENCY, ELEVATES NORTH AMERICA LEADERSHIP IN ENHANCED ORG STRUCTURE
Industry-leading leaders will drive growth for the agency's biggest market.NEW YORK, March 11, 2024 /PRNewswire/ -- Assembly announced today the elevations of Nicole Jennings to Managing Director, Br
Assembly Biosciences Executes Reverse Stock Split
Assembly Bio Enacts Reverse Stock Split to Meet Nasdaq Requirements
Assembly Biosciences To Carry Out 1-for-12 Reverse Stock Split On February 12th, 2024
February 9th - $Assembly Biosciences(ASMB.US)$ is about to implement a 1-for-12 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from February 12th, 2024.$Assembl
Assembly Biosciences Expects Its 1-for-12 Reverse Stock Split to Be Effective as of Feb 9 >ASMB
Assembly Biosciences Expects Its 1-for-12 Reverse Stock Split to Be Effective as of Feb 9 >ASMB
Assembly Biosciences Announces Effective Date of Reverse Stock Split
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 –SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasda
Analysis
Price Target
No Data
